Janus Henderson Group PLC Increases Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Janus Henderson Group PLC raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 31.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 66,726 shares of the medical instruments supplier's stock after acquiring an additional 15,892 shares during the period. Janus Henderson Group PLC owned approximately 0.30% of LeMaitre Vascular worth $6,149,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Graham Capital Management L.P. purchased a new stake in shares of LeMaitre Vascular in the 4th quarter valued at about $506,000. Deutsche Bank AG increased its position in shares of LeMaitre Vascular by 45.2% during the 4th quarter. Deutsche Bank AG now owns 18,462 shares of the medical instruments supplier's stock valued at $1,701,000 after purchasing an additional 5,747 shares during the last quarter. Corton Capital Inc. bought a new position in shares of LeMaitre Vascular during the 4th quarter valued at about $296,000. Cetera Investment Advisers increased its position in shares of LeMaitre Vascular by 11.5% during the 4th quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock valued at $254,000 after purchasing an additional 284 shares during the last quarter. Finally, Centiva Capital LP bought a new position in shares of LeMaitre Vascular during the 4th quarter valued at about $281,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective on the stock. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital raised their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Finally, Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.14.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This represents a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO George W. Lemaitre sold 4,399 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total value of $374,354.90. Following the completion of the transaction, the chief executive officer now owns 1,827,003 shares of the company's stock, valued at approximately $155,477,955.30. This trade represents a 0.24% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 102,009 shares of company stock worth $8,721,836. 9.50% of the stock is owned by corporate insiders.

LeMaitre Vascular Trading Up 2.9%

NASDAQ LMAT traded up $2.28 on Friday, hitting $81.40. The company's stock had a trading volume of 205,755 shares, compared to its average volume of 166,624. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The company's 50-day simple moving average is $84.26 and its 200 day simple moving average is $92.65. The firm has a market cap of $1.84 billion, a P/E ratio of 44.48, a PEG ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). The firm had revenue of $59.87 million during the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular's revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.44 earnings per share. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. LeMaitre Vascular's dividend payout ratio (DPR) is 40.40%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.